About Publications

Publications from the National Academies of Sciences, Engineering, and Medicine provide objective and straightforward advice to decision makers and the public. This site includes Health and Medicine Division (HMD) publications released after 1998. A complete list of HMD’s publications from its establishment in 1970 to the present is available as a PDF.


  • Race, Ethnicity, and Language Data: Standardization for ... Released: August 31, 2009
    The quality of health care in the United States is not optimal, and the pace of improvement is slow. In addition, disparities persist for specific population groups. A fundamental step in identifying which populations are most at risk is to col¬lect data on race, ethnicity, and English-language proficiency. The Institute of Medicine (IOM) formed the Subcommittee on Standardized Col¬lection of Race/Ethnicity Data for Healthcare Quality Improvement to examine ap¬proaches to standardization. In its 2009 report, Race, Ethnicity, and Language Data: Standardization for Health Care Quality Improvement, the subcommittee recommends collection of more granular ethnicity and language need according to national standards in addition to OMB race and Hispanic ethnicity categories.
  • Initial National Priorities for Comparative Effectiveness ... Released: June 30, 2009
    Clinical research presents health care providers with information on the natural history and clinical presentations of disease as well as diagnostic and treatment options. Comparative effectiveness research (CER) identifies what works best for which patients under what circumstances. Congress, in the American Recovery and Reinvestment Act (ARRA) of 2009, tasked the IOM to recommend national priorities for research questions to be addressed by CER and supported by ARRA funds. In its 2009 report, Initial National Priorities for Comparative Effectiveness Research, the authoring committee establishes a working definition of CER, develops a priority list of research topics, and identifies the necessary requirements to support a robust and sustainable CER enterprise.
  • Evidence-Based Medicine and the Changing Nature of ... Released: October 09, 2008
    Drawing on the work of the Roundtable on Evidence-Based Medicine, the 2007 IOM Annual Meeting assessed some of the rapidly occurring changes in health care related to new diagnostic and treatment tools, emerging genetic insights, the developments in information technology, and healthcare costs, and discussed the need for a stronger focus on evidence to ensure that the promise of scientific discovery and technological innovation is efficiently captured to provide the right care for the right patient at the right time.
  • From Molecules to Minds: Challenges for the 21st Century. ... Released: September 29, 2008
    On June 25, 2008, the IOM Forum on Neuroscience and Nervous System Disorders hosted more than 70 of the leading neuroscientists in the world, for a workshop titled From Molecules to Minds: Challenges for the 21st Century. The objective of the workshop was to explore a set of common goals or “Grand Challenges” posed by participants that could inspire and rally both the scientific community and the public to consider the possibilities for neuroscience in the 21st century.
  • Use of Dietary Supplements by Military Personnel : Health and ... Released: June 09, 2008
    The use of dietary supplements has become increasingly popular among members of the military. While some supplements may provide benefits to health, others could carry adverse effects that might compromise the readiness and performance of service members. The U.S. Department of Defense, the Samueli Institute, the National Institutes of Health (NIH), with additional support from the Food and Drug Administration (FDA), requested that the Institute of Medicine (IOM) review the use of dietary supplements by military personnel, recommending a framework to identify the need for management of dietary supplement use within the military, and developing an approach to report adverse health events.
  • Emerging Safety Science. Workshop Summary : Health and ... Released: April 09, 2008
    In April 2007, the Institute of Medicine’s Forum on Drug Discovery, Development, and Translation convened a workshop entitled “Emerging Safety Science” to examine the use of emerging safety science technologies in drug development and to consider their application in the drug review process. This publication summarizes the presentations and discussions during that workshop.
  • Cancer-Related Genetic Testing and Counseling. Workshop ... Released: August 20, 2007
    The Institute of Medicine’s National Cancer Policy Forum held a workshop and released the proceedings entitled Cancer-Related Genetic Testing and Counseling. The workshop focused on the fact that genetic testing and counseling are becoming more complex and important for informing patients and families of the risks and benefits of certain courses of action, but at the same time organized expert programs are in short supply. The workshop covered the scientific and clinical aspects of genetic testing and counseling as well as workforce and reimbursement issues, among others.
  • The Learning Healthcare System : Health and Medicine ... Released: March 30, 2007
    The Roundtable serves as a neutral venue for cooperative work among key stakeholders on several dimensions: to help transform the availability and use of the best evidence for the collaborative health care choices of each patient and provider; to drive the process of discovery as a natural outgrowth of patient care; and, ultimately, to ensure innovation, quality, safety, and value in health care.
  • Effect of the HIPAA Privacy Rule on Health Research ... Released: September 26, 2006
    Presentations described the regulations implemented in 2003 governing protection of the privacy of individually identifiable health information in health plans, providers, and clearinghouses that engage in electronic transactions.
  • The Future of Drug Safety: Promoting and Protecting the ... Released: September 22, 2006
    In response to growing public concern with health risks posed by approved drugs, U.S. Food and Drug Administration (FDA) and the Department of Health and Human Services announced a series of steps to address drug safety, including asking the IOM to convene a committee to assess the U.S. drug safety system and to make recommendations to improve risk assessment, surveillance, and the safe use of drugs. In its report, The Future of Drug Safety: Promoting and Protecting the Health of the Public, the committee considered the drug safety system as the sum of all activities conducted by FDA and other stakeholders to monitor, evaluate, improve, and ensure drug safety.